Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

ARQ 197 in Subjects With Metastatic Solid Tumors

Study:

A Phase 1 Dose Escalation Study of ARQ 197 in Adult Patients With Metastatic Solid Tumors

Rationale:

n/a

Purpose:

To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Cancer
Tumor
Drug: ARQ 197 Phase 1

Verified by ArQule August, 2009

Sponsored by: ArQule
Information provided by: ArQule
ClinicalTrials.gov identifier: NCT00302172

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Control: Uncontrolled, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

The Cleveland Clinic
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site